Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | PGK1 | P00558 | 1/20 | 0.35 |
| ▸ | PGK2 | P07205 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 11/20 | 0.35 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | TPO | P07202 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29710161 | 0.84 | CYP3A4 (0.39) | CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL23165941 | 0.84 | CYP3A4 (0.39) | CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL23701880 | 0.83 | AR (0.44) | AR | |
| SCHEMBL23713999 | 0.81 | CYP3A4 (0.37) | CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL23701905 | 0.80 | PGK1 (0.41) | CYP3A4CYP1A2CYP2C9PGK1PGK2 | |
| SCHEMBL23701887 | 0.80 | AR (0.47) | CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL23205995 | 0.73 | KMT2A (0.41) | CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL23701902 | 0.72 | HTT (0.56) | AR | |
| SCHEMBL18758436 | 0.72 | ALDH1A1 (0.38) | HDAC1HDAC6 | |
| SCHEMBL24196207 | 0.72 | HDAC1 (0.39) | HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238187-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238187-A1 | AZIRIDINE CONTAINING EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES | EPOR, EZR, CD47 | CYP3A4 780/4885CYP1A2 575/4885CYP2D6 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.